Daniel P. Petrylak, MD

Daniel P. Petrylak, MD, professor of medicine and urology and co-leader, Cancer Signaling Networks, Yale Cancer Center, discusses the efficacy results from the CARD trial, which evaluated the radiographic progression-free survival (rPFS) of cabazitaxel (Jevtana) combined with either abiraterone acetate (Zytiga) or enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer (mCRPC).

The results showed that the use of cabazitaxel achieved better rPFS than either second-generation antiandrogen. This suggests that patients still have resistance to second-generation hormonal agents but, currently, there is no algorithm for understanding which agent should be administered and when.

Videos

Daniel P. Petrylak, MD, discusses the efficacy results from the CARD trial, which evaluated the radiographic progression-free survival of cabazitaxel combined with either abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer.<br />
&nbsp;

Cabazitaxel Improves rPFS in Patients with mCRPC

Daniel P. Petrylak, MD, professor of medicine and urology at Yale Cancer Center, discusses the data from the phase II EV-201 trial investigating enfortumab vedotin as treatment of patients with locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy or a PD-1/PD-L1 checkpoint inhibitor.

Enfortumab vedotin has a unique mechanism of action, says Petrylak. It is an antibodydrug conjugate that targets Nectin-4, which is expressed in lower levels in normal tissue cells in bladder cancers. This agent is able to deliver chemotherapy directly to the cancer cells in this patient population. Petrylak says this targeted therapy could be considered a &ldquo;smart bomb&rdquo; based on this activity.

The drug is also well tolerated. In the case of patients developing neuropathy on treatment, holding or reducing enfortumab vedotin caused the neuropathy to go away.  In addition, if the patient had a pre-existing neuropathy, holding or reducing the drug also caused the toxicity to reduce. Petrylak notes similar effects in regard to diabetes or rash in this patient population.

Daniel P. Petrylak, MD, discusses the data from the phase II EV-201 trial investigating enfortumab vedotin as treatment of patients with locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy or a PD-1/PD-L1 checkpoint inhibitor.

Enfortumab Vedotin Appears Well-Tolerated and Active in Advanced Bladder Cancers

Daniel P. Petrylak, MD, a professor of Medicine and Urology and co-director of the Signal Transduction Research Program at Yale School of Medicine, discussed results from the phase III RANGE trial for the combination of ramucirumab (Cyramza) and docetaxel in patients with urothelial carcinoma.

These findings demonstrated a 25% reduction in the progression-free survival (PFS) rate in the group of patients receiving ramucirumab plus docetaxel, Petrylak says. The toxicities did not significantly increase with the addition of ramucirumab to the standard treatment of docetaxel.

Combination Ramucirumab and Docetaxel for Urothelial Carcinoma

Daniel P. Petrylak, MD,&nbsp;professor of Medicine and Urology, Yale Cancer Center, discusses studies evaluating second-line treatment options in bladder cancer.

Daniel P. Petrylak, MD | Authors

Articles

Cabazitaxel Improves rPFS in Patients with mCRPC

Enfortumab Vedotin Appears Well-Tolerated and Active in Advanced Bladder Cancers

Combination Ramucirumab and Docetaxel for Urothelial Carcinoma

Evaluating Second-Line Treatment Options in Bladder Cancer